Market Restructuring Through Generic Entry

Accord Healthcare has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the generic version of Dalfampridine extended-release tablets 10mg, used to improve walking ability in patients with Multiple Sclerosis (MS). This approval follows the expiration of the patent for the original drug, Ampyra, marketed by Acorda Therapeutics, and subsequent legal challenges, with market entry officially commencing on September 18, 2018. The entry of lower-priced generics into a market previously dominated by the original brand is poised to disrupt the existing pricing structure and significantly improve patient access to treatment.

Clinical Equivalence and Safety Validation

Dalfampridine works by blocking voltage-gated potassium channels in nerve fibers, thereby enhancing the conduction of action potentials in damaged demyelinated nerves. Accord Healthcare's generic product has been shown to be bioequivalent to the original drug, Ampyra, in terms of pharmacokinetic and pharmacodynamic profiles, as demonstrated in bioequivalence studies and confirmed by the FDA. However, Dalfampridine carries a significant risk of serious adverse effects, including seizures, in patients with renal impairment, as the drug's serum concentration can rise rapidly. Therefore, careful pre- and post-treatment monitoring of patients' renal function is essential, a guideline consistently followed throughout the industry.

Intensified Competition and Price Reduction Pressure

The original product, Ampyra, generated peak annual sales of USD 543 million in 2017 while holding patent exclusivity. However, following Acorda Therapeutics' loss in patent litigation, the entry of numerous generic products, including Accord Healthcare's, caused the original drug's sales to plummet by more than half within a year. In a market where Accord Healthcare must compete with global generic giants like Mylan and Teva for the same indications, securing price competitiveness and establishing a stable supply chain are top priorities.

Strategy for Formulary Listing and Prescription Acquisition

In the U.S. pharmaceutical market, the success of generic products largely depends on their inclusion in the preferred drug lists (Formulary) of Pharmacy Benefit Managers (PBMs). Generic pharmaceutical companies are employing a strategy of negotiating with private and public insurers to significantly reduce patient co-pays, thereby rapidly expanding their market share by leveraging lower prices. Given the inherent cost-saving benefits of generics for both patients and insurers, the rate of prescription switching is very rapid, making initial positioning in distribution channels a key factor in long-term revenue growth.